Pfizer Inc. $PFE Shares Sold by Qsemble Capital Management LP

Qsemble Capital Management LP reduced its position in Pfizer Inc. (NYSE:PFE) by 41.9% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 122,644 shares of the biopharmaceutical company’s stock after selling 88,473 shares during the quarter. Qsemble Capital Management LP’s holdings in Pfizer were worth $2,953,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Evolution Wealth Management Inc. boosted its holdings in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at approximately $26,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC increased its position in Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $26.88 on Tuesday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The company’s 50 day simple moving average is $25.15 and its 200 day simple moving average is $26.20. The company has a market capitalization of $153.21 billion, a price-to-earnings ratio of 35.37 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.Pfizer’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s dividend payout ratio is 226.32%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. JPMorgan Chase & Co. decreased their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. BMO Capital Markets lowered their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Guggenheim cut their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.